Amneal Pharmaceuticals (AMRX) Cost of Revenue (2017 - 2026)

Amneal Pharmaceuticals' Cost of Revenue history runs 10 years deep, the most recent figure standing at $402.4 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 8.45% year-over-year to $402.4 million; the TTM figure through Mar 2026 stood at $1.9 billion (up 4.26% YoY), while the FY2025 annual figure was $1.9 billion, up 7.44% from the prior year.
• Cost of Revenue was $402.4 million for Q1 2026 at Amneal Pharmaceuticals, down from $517.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $1.4 billion in Q4 2022 to a low of $764000.0 in Q1 2022.
• Historically, Cost of Revenue has averaged $394.3 million across 5 years, with a median of $427.2 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue sank 78.67% in 2022, then jumped 55001.59% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $1.4 billion in 2022, then tumbled by 70.02% to $427.2 million in 2023, then rose by 9.48% to $467.6 million in 2024, then rose by 10.58% to $517.1 million in 2025, then fell by 22.18% to $402.4 million in 2026.
• The last three Cost of Revenue figures came in at $402.4 million (Q1 2026), $517.1 million (Q4 2025), and $510.5 million (Q3 2025), per Business Quant data.